Сравнение

Lanreotid vs. Linaclotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

108736-35-2

851199-59-2

Молекулярная масса

1096.34 g/mol

1526.74 g/mol

Период полувыведения

нет данных

Последовательность

нет данных

Механизм действия

Lanreotid

Lanreotide activates somatostatin receptors (chiefly SSTR2, additionally SSTR5), thereby suppressing the release of growth hormone, IGF-1 and various gastrointestinal and neuroendocrine hormones. It is metabolically far more stable than natural somatostatin.

Linaclotid

Linaclotide activates the guanylate cyclase-C receptor on the luminal surface of the intestinal epithelium. This raises cyclic GMP (cGMP), increases secretion of chloride and bicarbonate into the lumen, raises stool fluid content and accelerates transit; pain signaling is also modulated.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Lanreotid	Linaclotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Lanreotid and Linaclotid?: Lanreotid is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Lanreotid or Linaclotid?: The highest available evidence level is "РКИ на людях" for Lanreotid and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Lanreotid and Linaclotid in Germany and the United States?: Германия: Lanreotid — Рецептурный, Linaclotid — Рецептурный. США: Lanreotid — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Lanreotid

Linaclotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Lanreotid and Linaclotid?

Lanreotid is classified as "Исследования (прочее)", while Linaclotid is classified as "Исследования (прочее)". Lanreotid: Lanreotide is a synthetic cyclic octapeptide analog of somatostatin. It binds preferentially to the somatostatin receptors SSTR2 and SSTR5 and is approved for treating acromegaly and certain neuroendocrine tumours. Linaclotid: Linaclotide is a 14-amino-acid peptide and guanylate cyclase-C (GC-C) agonist. It is approved for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Lanreotid or Linaclotid?

The highest available evidence level is "РКИ на людях" for Lanreotid and "РКИ на людях" for Linaclotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Lanreotid and Linaclotid in Germany and the United States?

Германия: Lanreotid — Рецептурный, Linaclotid — Рецептурный. США: Lanreotid — Рецептурный, Linaclotid — Рецептурный. These are factual summaries with source and review date on the individual pages.